Coronado Biosciences Inc (NASDAQ:CNDO) investors should be aware of an increase in support from the world’s most elite money managers lately.
If you’d ask most market participants, hedge funds are viewed as worthless, old financial vehicles of years past. While there are more than 8000 funds in operation at present, we at Insider Monkey look at the top tier of this group, about 450 funds. Most estimates calculate that this group oversees most of all hedge funds’ total capital, and by paying attention to their best investments, we have deciphered a few investment strategies that have historically beaten the market. Our small-cap hedge fund strategy outstripped the S&P 500 index by 18 percentage points per year for a decade in our back tests, and since we’ve started sharing our picks with our subscribers at the end of August 2012, we have outclassed the S&P 500 index by 23.3 percentage points in 8 months (explore the details and some picks here).
Just as beneficial, optimistic insider trading sentiment is another way to break down the investments you’re interested in. Obviously, there are many stimuli for an executive to cut shares of his or her company, but only one, very clear reason why they would behave bullishly. Many empirical studies have demonstrated the impressive potential of this tactic if “monkeys” know what to do (learn more here).
Consequently, let’s take a gander at the recent action surrounding Coronado Biosciences Inc (NASDAQ:CNDO).
How have hedgies been trading Coronado Biosciences Inc (NASDAQ:CNDO)?
Heading into Q2, a total of 5 of the hedge funds we track were bullish in this stock, a change of 25% from the first quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists an “upper tier” of notable hedge fund managers who were increasing their holdings considerably.
Of the funds we track, Paul Singer’s Elliott Management had the biggest position in Coronado Biosciences Inc (NASDAQ:CNDO), worth close to $36.2 million, accounting for 0.8% of its total 13F portfolio. On Elliott Management’s heels is Driehaus Capital, managed by Richard Driehaus, which held a $2.2 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Some other peers with similar optimism include Andrew Spokes’s Farallon Capital, Jim Simons’s Renaissance Technologies and Israel Englander’s Millennium Management.
Now, specific money managers have jumped into Coronado Biosciences Inc (NASDAQ:CNDO) headfirst. Farallon Capital, managed by Andrew Spokes, initiated the most valuable position in Coronado Biosciences Inc (NASDAQ:CNDO). Farallon Capital had 1 million invested in the company at the end of the quarter. Jim Simons’s Renaissance Technologies also made a $0.4 million investment in the stock during the quarter. The only other fund with a brand new CNDO position is Israel Englander’s Millennium Management.
What do corporate executives and insiders think about Coronado Biosciences Inc (NASDAQ:CNDO)?
Insider buying is at its handiest when the primary stock in question has experienced transactions within the past six months. Over the last half-year time frame, Coronado Biosciences Inc (NASDAQ:CNDO) has seen 3 unique insiders purchasing, and zero insider sales (see the details of insider trades here).
Let’s also review hedge fund and insider activity in other stocks similar to Coronado Biosciences Inc (NASDAQ:CNDO). These stocks are Insmed Incorporated (NASDAQ:INSM), Curis, Inc. (NASDAQ:CRIS), Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), GTx, Inc. (NASDAQ:GTXI), and Threshold Pharmaceuticals, Inc. (NASDAQ:THLD). This group of stocks belong to the biotechnology industry and their market caps are closest to CNDO’s market cap.